What is Criterion Edge?
Founded in 2016, Criterion Edge has carved a niche by providing high-quality regulatory writing services tailored to the stringent requirements of the Medical Device, Biopharma/Pharma, and In-Vitro Diagnostic Device industries. The company serves a diverse clientele, from emerging startups to established corporations, by delivering compliant and effective regulatory documentation. Criterion Edge's core strength lies in its multidisciplinary team of medical writers and quality assurance professionals who collaborate to ensure precision and adherence to global standards. Their commitment to flexibility and rigorous quality control is designed to expedite client approval timelines and optimize the regulatory submission process.
How much funding has Criterion Edge raised?
Criterion Edge has raised a total of $345K across 2 funding rounds:
Debt
$150K
Debt
$195K
Debt (2020): $150K with participation from PPP
Debt (2021): $195K led by PPP
What's next for Criterion Edge?
With its recent strategic investment and substantial total funding of $345K, Criterion Edge is poised for accelerated expansion. The company is likely to leverage this capital infusion to enhance its service capabilities, potentially investing in advanced technology for document management and compliance tracking. Furthermore, the financing may support strategic hiring to bolster its expert team, enabling Criterion Edge to cater to an increasing volume of complex regulatory projects. This strategic backing positions the company to further solidify its reputation as a leading provider of regulatory writing solutions, driving innovation and efficiency in the life sciences sector.
See full Criterion Edge company page
